Published in Oncotarget on March 07, 2017
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg (2001) 11.58
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol (2006) 11.56
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell (2009) 6.77
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (2016) 6.24
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol (2014) 5.21
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol (2005) 4.10
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther (2007) 2.89
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol (2001) 2.81
Polymer-based nanocapsules for drug delivery. Int J Pharm (2009) 2.03
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94
History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev (2009) 1.88
Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release (2007) 1.73
A review of brain aromatase cytochrome P450. Brain Res Brain Res Rev (1996) 1.61
Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab (2002) 1.39
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials (2011) 1.36
Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg (1996) 1.36
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res (2010) 1.35
Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets (2010) 1.28
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet (2013) 1.24
The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry (1990) 1.22
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget (2012) 1.22
The multiple roles of estrogens and the enzyme aromatase. Prog Brain Res (2010) 1.20
Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol (2006) 1.19
Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol (2010) 1.13
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol (2005) 1.08
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 1.06
MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis (2013) 1.04
Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol (2007) 1.04
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. MAbs (2013) 0.97
Optimization of antibody-conjugated magnetic nanoparticles for target preconcentration and immunoassays. Anal Biochem (2010) 0.96
Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis (2014) 0.95
Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc(-), leading to glutathione depletion. Oncogene (2015) 0.94
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer (2010) 0.91
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J (2010) 0.90
Influence of PEG in PEG-PLGA microspheres on particle properties and protein release. Eur J Pharm Biopharm (2012) 0.90
Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res (2014) 0.90
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat (1994) 0.90
Development and validation of a spectrophotometric method for estimation of letrozole in bulk and pharmaceutical formulation. Pharmazie (2007) 0.89
miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPβ. Oncotarget (2015) 0.88
MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma. Sci Rep (2015) 0.87
Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci (2015) 0.87
Human glioma-initiating cells show a distinct immature phenotype resembling but not identical to NG2 glia. J Neuropathol Exp Neurol (2013) 0.87
CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. PLoS One (2015) 0.86
Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Ther (2000) 0.86
Tissue physiology and pathology of aromatase. Steroids (2011) 0.85
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol (2003) 0.84
HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. Sci Rep (2015) 0.83
Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther (2014) 0.82
The role of estrogen and estrogen receptors in chemoresistance. Curr Med Chem (2011) 0.82
Controlled and sustained gene delivery from injectable, porous PLGA scaffolds. J Biomed Mater Res A (2011) 0.82
Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. J Neurosurg (2016) 0.81
Inhibition of miR-191 contributes to radiation-resistance of two lung cancer cell lines by altering autophagy activity. Cancer Cell Int (2015) 0.81
CD90 is identified as a marker for cancer stem cells in high-grade gliomas using tissue microarrays. Neurosurgery (2012) 0.80
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. Cancer Chemother Pharmacol (2013) 0.80
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. Br J Cancer (2015) 0.79
The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells. Biomaterials (2013) 0.79
Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients. Int J Biol Markers (2015) 0.78
Highly compacted pH-responsive DNA nanoparticles mediate transgene silencing in experimental glioma. J Mater Chem B Mater Biol Med (2014) 0.77
Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Sci Rep (2016) 0.76
Modulation of Aromatase by Phytoestrogens. Enzyme Res (2015) 0.76
Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma. Biomaterials (2016) 0.76
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Rev Clin Pharmacol (2016) 0.76
Nanoparticle transport across the blood brain barrier. Tissue Barriers (2016) 0.76
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness. Anat Cell Biol (2015) 0.76
Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas. Mol Cancer Ther (2015) 0.76
Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget (2016) 0.76
MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. Tumour Biol (2015) 0.76